EpCAM-targeted ZIF-8 nanocarriers for enhanced doxorubicin delivery in cancer therapy: a promising approach for tumor-specific drug release

AI Insight

This study describes the development of ZIF-8 (zeolitic imidazolate framework-8) nanoparticles functionalized with EpCAM antibodies to deliver doxorubicin specifically to cancer cells. The EpCAM-targeting mechanism allows selective binding to tumor cells that overexpress this surface marker, while the pH-sensitive ZIF-8 framework enables controlled drug release in the acidic tumor microenvironment. The nanocarrier system demonstrated improved tumor accumulation and reduced systemic toxicity compared to free doxorubicin in preclinical models.

Why it matters

This targeted delivery approach could potentially reduce the severe side effects associated with conventional chemotherapy by concentrating the drug at tumor sites while sparing healthy tissues. The system represents a step toward personalized cancer treatment, particularly for tumors with high EpCAM expression such as colorectal, breast, and ovarian cancers.